non-small cell lung cancer
Conditions
Interventions
S1 is administered orally twice daily for 14 days a day, according to the body surface area, followed by 7 days off. PTX 80 mg / m 2 is administered on Day 1, 8 by drip infusion. One cycle is 21 days.
Sponsors
Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) A case in which definitive diagnosis of non-small cell lung cancer was obtained by histology or cytology 2) Cases with measurable lesions 3) Patients with a history of chemotherapy treatment containing 1 platinum regimen over 1 regimen (treatment history of surgical therapy and radiotherapy is not limited) 4) Cases with 4 weeks or more have passed since the end of previous chemotherapy 5) Case of over 20 years old 6) Case of Performance Status 0-1 of ECOG 7) Cases with sufficient bone marrow function and organ function 8) Cases in which survival for more than 2 months can be expected 9) Cases with oral administration 10) Case informed consent obtained document from patient himself
Exclusion criteria
Exclusion criteria: 1: Cases with serious complications Interstitial pneumonia Serious heart disease diabetes which is difficult to control Serious infectious diseases 2: Cases with other active organs and overlapping cancers 3: Patients with a history of severe hypersensitivity 4: Case in which flucytosine is being administered 5) Cases with a history of alcohol hypersensitivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival Overall survival safety | — |
Countries
Japan
Contacts
Public ContactYusuke Chihara
Kyoto Prefectural University of Medicine Department of Pulmonary Medicine
Outcome results
None listed